Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

AKRO holding history

Akero Therapeutics, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of AKRO by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−339,922−100.0%Sold outHolders
Q3 2025339,922$16.1M<0.1%−353,334−51.0%ReducedHolders
Q2 2025693,256$37.0M<0.1%−109,598−13.7%ReducedHolders
Q1 2025802,854$32.5M<0.1%+331,319+70.3%AddedHolders
Q4 2024471,535$13.1M<0.1%+23,465+5.2%AddedHolders
Q3 2024448,070$12.9M<0.1%−498,458−52.7%ReducedHolders
Q2 2024946,528$22.2M<0.1%+542,665+134.4%AddedHolders
Q1 2024403,863$10.2M<0.1%−653,464−61.8%ReducedHolders
Q4 20231,057,327$24.7M<0.1%+617,591+140.4%AddedHolders
Q3 2023439,736$22.2M<0.1%+54,078+14.0%AddedHolders
Q2 2023385,658$18.0M<0.1%+28,065+7.8%AddedHolders
Q1 2023357,593$13.7M<0.1%+150,593+72.8%AddedHolders
Q4 2022207,000$11.3M<0.1%+13,747+7.1%AddedHolders
Q3 2022193,253$6.58M<0.1%+54,050+38.8%AddedHolders
Q2 2022139,203$1.32M<0.1%−27,848−16.7%ReducedHolders
Q1 2022167,051$2.37M<0.1%+97,627+140.6%AddedHolders
Q4 202169,424$1.47M<0.1%+12,175+21.3%AddedHolders
Q3 202157,249$1.28M<0.1%−32,354−36.1%ReducedHolders
Q2 202189,603$2.22M<0.1%+59,413+196.8%AddedHolders
Q1 202130,190$876.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.